The information below is updated as of August, 2018. A database on availability and reimbursement can be found on . The reimbursement, instead, is made at the Regional level and unfortunately, there is no publicly available database on the topic. For more information, contact your Regional Sickness Fund (Regionale Strukturpläne Gesundheit, RSG). Their contacts are provided at .

Active Substance Indication Availability and Reimbursement Comments
Atezolizumab Carcinoma, Non-Small-Cell Lung Carcinoma, Transitional Cell Available
Avelumab Carcinoma, Merkel Cell Available
Bevacizumab Breast Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Ovarian Neoplasms Not available
Blinatumomab Precursor Cell Lymphoblastic Leukemia-Lymphoma Available
Brentuximab vedotin Hodgkin Disease Lymphoma, Non-Hodgkin Available
Cetuximab Colorectal Neoplasms Head and Neck Neoplasms Available
Daratumumab Multiple Myeloma Available
Denosumab Prevention of Bone Neoplasms-related complications Giant cell tumour, Bone Available and reimbursed at the Federal Level
Dinutuximab beta Neuroblastoma Not available
Elotuzumab Multiple Myeloma Available
Gemtuzumab ozogamicin Leukemia, Myeloid, Acute Available
Ibritumomab tiuxetan Lymphoma, Follicular Available
Inotuzumab ozogamicin Precursor Cell Lymphoblastic Leukemia-Lymphoma Available
Ipilimumab Melanoma Available
Necitumumab Carcinoma, Non-Small-Cell Lung Available
Nivolumab Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Hodgkin Disease Melanoma Available
Obinutuzumab Leukemia, Lymphocytic, Chronic, B-Cell Available
Ofatumumab Leukemia, Lymphocytic, Chronic, B-Cell Available
Olaratumab Sarcoma Available
Panitumumab Colorectal Neoplasms Available
Pembrolizumab Carcinoma, Non-Small-Cell Lung Hodgkin Disease Melanoma Available
Pertuzumab Breast Neoplasms Available
Ramucirumab Stomach Neoplasms Available
Rituximab Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin Available
Trastuzumab Breast Neoplasms Stomach Neoplasms Available
Trastuzumab emtansine Breast Neoplasms Available
Talimogene laherparepvec (t-vec) Melanoma Available

DISCLAIMER1: This website is intended for informative purposes only, and it does not create any rights. The information displayed in this website has been obtained from publicly available sources and collected by the European Cancer Patient Coalition, Specific restrictions, lack of information on availability and/or reimbursement may exist, even depending on indications or doses, and may vary between countries. Medicines may also be used for indications other than those officially authorised by the European Medicines Agency, and may also be prescribed off-label, depending on the doctor's advice or hospital practice. Final reimbursement quantities and conditions may also depend on applicable insurance schemes or hospital practices. If you have been diagnosed with cancer, please always check with your doctor and healthcare provider to confirm the specific conditions applying to your situation.